Price (delayed)
$20.96
Market cap
$2.56B
P/E Ratio
12.7
Dividend/share
N/A
EPS
$1.65
Enterprise value
$1.98B
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK
There are no recent dividends present for CPRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.